Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill takes on hard-to-treat blood cancers in early trial

NCT ID NCT06980116

Disease control Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-stage study tests an experimental drug called EXS73565 in about 50 adults with certain blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Participants take the drug by mouth and are closely monitored for side effects and cancer response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 85 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Age ≥18 years at the time of signing the informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia. * Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy Key Exclusion Criteria: * Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study. * Known central nervous system (CNS) malignancy or primary CNS lymphoma. * Concurrent active or previous malignancy (other than the primary lymphoma/CLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval. * Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma follicular lymphoma interdigitating dendritic cell sarcoma Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma marginal zone lymphoma Recurrence Richter transformation Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Diffuse large B cell lymphoma (DLBCL) Follicular lymphoma (FL) Mantle cell lymphoma (MCL) Marginal zone lymphoma (MZL) Relapsed or refractory B-cell malignancies Waldenstrom's macroglobulinemia (WM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    17 sites in 7 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Aidport Sp. z o.o. - PPDS

    RECRUITING

    Skórzewo, 60-185, Poland

  • Clinica Universidad de Navarra

    RECRUITING

    Pamplona, 31008, Spain

  • General Hosptial of Thessaloniko G. Papanikolaou

    RECRUITING

    Thessaloniki, 570 10, Greece

  • Hospital Beata Maria Ana

    RECRUITING

    Madrid, 28007, Spain

  • Hospital Fundación Jiménez Diaz

    RECRUITING

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro

    RECRUITING

    Madrid, Spain

  • IMSP Institute of Oncology, ARENSIA Exploratory Medicine

    RECRUITING

    Chisinau, MD-2025, Moldova

  • LLC ARENSIA Exploratory Medicine

    RECRUITING

    Tbilisi, 119, Georgia

  • Laiko General Hospital of Athens

    RECRUITING

    Athens, 115 26, Greece

  • MD Anderson Cancer Center Madrid

    RECRUITING

    Madrid, 28033, Spain

  • Medical Center of LLC ARENSIA Exploratory Medicine

    RECRUITING

    Kyiv, 01135, Ukraine

  • Pratia MCM

    RECRUITING

    Krakow, 30-727, Poland

  • St James's University Hospital

    RECRUITING

    Leeds, United Kingdom

  • University General Hospital of Patras

    RECRUITING

    Pátrai, 2650, Greece

  • University Hospitals Plymouth NHS Trust (Derriford Hospital)

    RECRUITING

    Plymouth, United Kingdom

  • Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie

    RECRUITING

    Lublin, 20-090, Poland

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologi (Copernicus Memorial Hospital)

    RECRUITING

    Lodz, 95-513, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.